Non-Intubated Uniportal Subxiphoid VATS Thymectomy for Myasthenia Gravis: A Case Report with review of literature
DOI:
https://doi.org/10.3126/njc.v10i1.93756Keywords:
Thymectomy, Myasthenia gravis, Uniportal, SubxiphoidAbstract
Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness caused by antibodies against components of the neuromuscular junction, most commonly the acetylcholine receptor (AChR). Thymectomy is an established treatment for patients with MG, particularly those with AChR antibodies. Recently, uniportal subxiphoid has become the approach of choice offering improved postoperative recovery and reduced complications. Non-intubated thoracic surgery has also gained attention for minimizing anesthetic-related complications in MG patients.
Case: Twenty two year old female diagnosed with AChR-positive, muscle specific tyrosine kinase (MuSK) negative MG receiving pyridostigmine who underwent uniportal subxiphoid VATS (Video assisted thoracoscopic surgery) thymectomy using local anesthesia and laryngeal mask airway (LMA) without muscle relaxant at B.P. Koirala Memorial Cancer Hospital (BPKMCH), Nepal. Preoperative evaluation
included neurological assessment, serological testing, and radiologic imaging. The procedure was successfully completed without conversion to open surgery or endotracheal intubation. Postoperatively, the patient experienced an uneventful recovery and at 6 months follow up she was symptom free with reduced dose of pyridostigmine.
Conclusion: Non-intubated uniportal subxiphoid VATS thymectomy is a safe and effective surgical option for MG patients. This technique may reduce postoperative complications and facilitate faster recovery compared with conventional intubated approaches. Our case highlights the potential benefits of minimally invasive thymectomy combined with non-intubated anesthesia in the management of myasthenia gravis.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Nepalese Journal of Cancer

This work is licensed under a Creative Commons Attribution 4.0 International License.
This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as NJC and the authors are acknowledged.
Submission of the manuscript means that the authors agree to assign exclusive copyright to NJC. The aim of NJC is to increase the visibility and ease of use of open access scientific and scholarly articles thereby promoting their increased usage and impact.